Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Vitrolife AB (0YAY) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Vitrolife AB SEK 14.75, price SEK 92.78, upside -84.1%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
VA
Thin data
Sep 23, 2026
Vitrolife AB
0YAY · LSEStretched ValuationStrong overvaluation with only moderate quality.
!Fair value kr 14.75 · Strongly overvalued (−84.1%)
!Quality 52/100
!Mixed Growth (revenue 5y +22.5 %/yr)
!Loss-making · -147.0% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 32/100
!Evidence only low, so the estimate is less certain
Watch Vitrolife AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range kr 85.40 – kr 551.71 · fair‑value band kr 8.90 – kr 20.97 · the kr 92.78 price screens above the kr 14.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Company profile
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits.
Show more
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Stock analysis
Vitrolife AB (0YAY) currently trades at kr 92.78, while our model-based Fair Value estimate is kr 14.75, 84.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 20.77 per share, and 0 of the 15 models we run sit above the kr 92.78 price.
Bear case: the Dividend Discount group reads lowest at kr 3.99, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 8.90 (bear) to kr 20.97 (bull), the price of kr 92.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vitrolife AB reported revenue of 3.4B SEK in FY2025 versus 1.7B SEK in FY2021, a compound +19.6%/yr. Reported net income was −5.0B SEK in FY2025.
Key figures
Market cap 52.4B SEK (≈ $5.2B) · P/S ratio 15.5 · Dividend yield 0.3% · Net margin −146% · Return on equity −46.5% · Return on assets (EBIT) 4.0% · Operating margin 23.1% · Revenue (TTM) 3.4B SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −84%, 0YAY screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 3.99 to kr 33.56). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 8.90
Fair Value kr 14.75
Bull kr 20.97
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
kr 11.23
kr 19.01
kr 38.21
76
Growth DCF
kr 10.92
kr 20.19
kr 34.34
76
EPV
kr 9.30
kr 10.54
kr 11.61
74
All 15 models by family
DCF Models
FCF DCF
kr 11.23
kr 19.01
kr 38.21
76
5Y Revenue Exit
kr 11.43
kr 20.77
kr 34.19
70
5Y EBITDA Exit
kr 17.16
kr 33.56
kr 55.64
73
10Y Revenue Exit
kr 10.93
kr 19.94
kr 35.38
64
10Y EBITDA Exit
kr 15.13
kr 29.55
kr 54.38
65
Earnings-Based
EPV
kr 9.30
kr 10.54
kr 11.61
74
Dividend Discount
Gordon GGM
kr 2.32
kr 4.62
kr 6.99
67
DDM Multi-Stage
kr 2.32
kr 3.99
kr 4.87
67
Multiples
EV/EBIT
kr 15.33
kr 19.97
kr 24.60
66
EV/EBITDA
kr 20.81
kr 27.28
kr 33.74
67
EV/Revenue
kr 11.35
kr 15.60
kr 19.86
54
Asset-Based
NCAV (Graham)
kr 6.99
kr 9.36
kr 13.97
54
Growth DCF
Growth DCF
kr 10.92
kr 20.19
kr 34.34
76
Rev-Margin DCF
kr 11.43
kr 20.34
kr 32.87
71
Economic Profit
ROIC Compounder
kr 9.30
kr 10.54
kr 11.61
72
Notify me when 0YAY reaches fair value
Put 0YAY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
52/100
Of which business quality 51 · Market factors (momentum, volatility) 23
Profitability
9
Margins and returns on capital today
Quality Growth
20
Are margins and returns improving?
Cashflow
52
Earnings quality: real cash, not paper profit
Fin. Strength
73
Balance sheet, leverage, solvency risk
Investment
89
Disciplined investing over empire-building
Low Volatility
27
Calm price path (market factor)
Momentum
30
Price trend over the last 3–12 months (market factor)
52W Momentum
6
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
33.0% (2019) → 21.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +22.3% a year for the price and +3.0% for the forecasts.
Forecast 2026 (sales)+0.5%
Forecast 2027 (sales)+7.2%
Projected 2028 (sales)+6.6%
Projected 2029 (sales)+5.9%
Projected 2030 (sales)+5.3%
0YAY screens overvalued: fair value 84% below the price. Compare with Abbott Laboratories, →
Compare Vitrolife AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Edwards Lifesciences Corporation EW | $85.19 | $81.94 | −4% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| Koninklijke Philips N.V PHIA | €21.87 | €15.23 | −30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Vitrolife AB (0YAY) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 14.75 versus a price of kr 92.78, about −84% upside (overvalued).
What is the fair value of 0YAY?
Our model-based fair value for Vitrolife AB is kr 14.75 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 92.78.
What is the quality score of 0YAY?
Vitrolife AB has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vitrolife AB (0YAY)?
Our model-based price target is the fair value of kr 14.75 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario kr 8.90, optimistic scenario kr 20.97. It is a calculation from audited fundamentals, not an analyst target.
What is the Vitrolife AB stock forecast for 2026?
Our models put fair value at kr 14.75, about −84% upside versus a price of kr 92.78 (overvalued). Cautious scenario kr 8.90, optimistic scenario kr 20.97. The calculation is refreshed regularly with new filings.
What is the revenue of Vitrolife AB (0YAY)?
Vitrolife AB reported trailing-twelve-month revenue of about 3.4B SEK (latest available figure, as of Sep 23, 2026).
Does Vitrolife AB pay a dividend?
Vitrolife AB currently shows a dividend yield of about 0.28% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Vitrolife AB (0YAY)?
For today's price to be fair in a discounted-cash-flow model, Vitrolife AB would have to grow free cash flow by +24.7 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 0YAY use?
Our models discount Vitrolife AB at 12.1 %: a base by market capitalisation (mid), damped by beta 1.71, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vitrolife AB that is +24.7 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Vitrolife AB (0YAY) delivered so far?
Over the past 5 years revenue at Vitrolife AB grew +22.5 % a year. The price currently implies +24.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vitrolife AB (0YAY) growing?
The median revenue growth in the sector is +7.0 % a year. That is the yardstick for the growth priced into Vitrolife AB (+24.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vitrolife AB (0YAY)?
The free-cash-flow yield on the price is 2.91 %: that much free cash flow Vitrolife AB produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vitrolife AB (0YAY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vitrolife AB it is kr 14.75 per share (as of Sep 23, 2026), against a price of kr 92.78. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Vitrolife AB stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0YAY trades above its calculated fair value: price kr 92.78, fair value kr 14.75, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0YAY?
No. The price is what the market pays today (kr 92.78); the fair value is what the company's own numbers justify (kr 14.75). For Vitrolife AB the two are kr 78.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vitrolife AB worth?
The market values Vitrolife AB at about 52.4B SEK (market capitalisation, as of Sep 23, 2026). Per share that is kr 92.78; our models calculate a fair value of kr 14.75 per share.
What do the bullish and bearish scenarios say about 0YAY?
Our models span a range for Vitrolife AB: cautious scenario kr 8.90, base kr 14.75, optimistic kr 20.97 per share (as of Sep 23, 2026, price kr 92.78). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vitrolife AB (0YAY)?
Balance-sheet figures for Vitrolife AB (as of Sep 23, 2026): return on equity −46.5%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 0YAY from its 52-week high?
Vitrolife AB trades at kr 92.78, about 39% below its 52-week high of kr 150.90 and 9% above the low of kr 85.40 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 14.75 is for.
Which stocks are comparable to Vitrolife AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vitrolife AB stock attractive at the current price?
The data as of Sep 23, 2026: price kr 92.78, calculated fair value kr 14.75 (−84%), Quality Score 52/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0YAY calculated?
We run Vitrolife AB through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 14.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vitrolife AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vitrolife AB (0YAY)?
The closing price on Oct 2, 2026 was kr 92.78. Our model-based fair value is kr 14.75, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vitrolife AB right now?
The price sits above even our optimistic bull case (kr 20.97). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 8.90 to kr 20.97) leaves room in how you read the outcome.
Key figures of Vitrolife AB
How large is the market capitalisation of Vitrolife AB (0YAY)?
The market capitalisation of Vitrolife AB is 52.4B SEK (≈ $5.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vitrolife AB (0YAY)?
The price-to-sales ratio of Vitrolife AB is 15.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Vitrolife AB (0YAY)?
The dividend yield of Vitrolife AB is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vitrolife AB (0YAY)?
The net margin of Vitrolife AB is −146% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vitrolife AB (0YAY)?
The return on equity (ROE) of Vitrolife AB is −46.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vitrolife AB (0YAY)?
On an EBIT basis the return on assets of Vitrolife AB is 4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vitrolife AB (0YAY)?
The operating margin of Vitrolife AB is 23.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vitrolife AB (0YAY)?
Revenue at Vitrolife AB is growing −1.6% versus a year earlier (3y avg +2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vitrolife AB (0YAY)?
Earnings per share at Vitrolife AB are growing +28.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vitrolife AB (0YAY) carry?
The net debt of Vitrolife AB is 868M SEK (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vitrolife AB in the live analysis
One click puts Vitrolife AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.